Type 2 Diabetes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Type 2 diabetes is the most common form of diabetes. The symptoms include fatigue, weight issues, vision deficits, and various other effects. Risk factors include family history, age, obesity, physical inactivity, and high blood pressure.

The Type 2 Diabetes pipeline drugs market research report provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report reviews key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects.

Type 2 Diabetes Pipeline Drugs Market Segmentation by Targets

Some of the key targets of the Type 2 Diabetes pipeline drugs market are Glucagon Like Peptide 1 Receptor, Insulin Receptor, Dipeptidyl Peptidase 4, Sodium/Glucose Cotransporter 2, Adenosine Monophosphate Activated Protein Kinase, Glucagon Receptor, Gastric Inhibitory Polypeptide Receptor, Glucokinase, Glucagon Like Peptide 1, and Free Fatty Acid Receptor 1.

Type 2 Diabetes Pipeline Drugs Market Analysis, by Targets

Type 2 Diabetes Pipeline Drugs Market Analysis, by Targets

For more Type 2 Diabetes pipeline drugs market target insights, download a free report sample

Type 2 Diabetes Pipeline Drugs Market Segmentation by Mechanisms of Action

Some of the key mechanisms of action of the Type 2 Diabetes pipeline drugs market are Glucagon Like Peptide 1 Receptor Agonist, Insulin Receptor Agonist, Dipeptidyl Peptidase 4 Inhibitor, Sodium/Glucose Cotransporter 2 Inhibitor, Adenosine Monophosphate Activated Protein Kinase Activator, Gastric Inhibitory Polypeptide Receptor Agonist, Glucagon Receptor Agonist, Glucokinase Activator, Glucagon Like Peptide 1 Activator, and Free Fatty Acid Receptor 1 Agonist.

Type 2 Diabetes Pipeline Drugs Market Analysis, by Mechanisms of Action

Type 2 Diabetes Pipeline Drugs Market Analysis, by Mechanisms of Action

For more mechanism of action insights into the Type 2 Diabetes pipeline drugs market, download a free report sample

Type 2 Diabetes Pipeline Drugs Market Segmentation by Routes of Administration

Some of the key routes of administration in the Type 2 Diabetes pipeline drugs market are oral, subcutaneous, parenteral, intravenous, transdermal, buccal, sublingual, inhalational, topical, and cutaneous.

Type 2 Diabetes Pipeline Drugs Market Analysis, by Routes of Administration

Type 2 Diabetes Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the Type 2 Diabetes pipeline drugs market, download a free report sample

Type 2 Diabetes Pipeline Drugs Market Segmentation by Molecule Types

Some of the key molecule types in the Type 2 Diabetes pipeline drugs market are small molecule, recombinant protein, synthetic peptide, peptide, fusion protein, recombinant peptide, cell therapy, biologic, monoclonal antibody, and gene therapy.

Type 2 Diabetes Pipeline Drugs Market Analysis, by Molecule Types

Type 2 Diabetes Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights into the Type 2 Diabetes pipeline drugs market, download a free report sample

Type 2 Diabetes Pipeline Drugs Market - Competitive Landscape

Some of the leading companies in the Type 2 Diabetes pipeline drugs market are Eli Lilly and Co, Tonghua Dongbao Pharmaceutical Co Ltd, Novo Nordisk AS, Merck & Co Inc, Jiangsu Hengrui Medicine Co Ltd, AstraZeneca Plc, Sihuan Pharmaceutical Holdings Group Ltd, Adocia SAS, Chong Kun Dang Pharmaceutical Corporation, and Intarcia Therapeutics Inc.

Type 2 Diabetes Pipeline Drugs Market Analysis, by Companies

Type 2 Diabetes Pipeline Drugs Market Analysis, by Companies

To know more about the companies in the Type 2 Diabetes pipeline drugs market, download a free report sample

Type 2 Diabetes Pipeline Drugs Market Report Overview

Key Targets Glucagon Like Peptide 1 Receptor, Insulin Receptor, Dipeptidyl Peptidase 4, Sodium/Glucose Cotransporter 2, Adenosine Monophosphate Activated Protein Kinase, Glucagon Receptor, Gastric Inhibitory Polypeptide Receptor, Glucokinase, Glucagon Like Peptide 1, and Free Fatty Acid Receptor 1
Key Mechanisms of Action Glucagon Like Peptide 1 Receptor Agonist, Insulin Receptor Agonist, Dipeptidyl Peptidase 4 Inhibitor, Sodium/Glucose Cotransporter 2 Inhibitor, Adenosine Monophosphate Activated Protein Kinase Activator, Gastric Inhibitory Polypeptide Receptor Agonist, Glucagon Receptor Agonist, Glucokinase Activator, Glucagon Like Peptide 1 Activator, and Free Fatty Acid Receptor 1 Agonist
Key Routes of Administration Oral, Subcutaneous, Parenteral, Intravenous, Transdermal, Buccal, Sublingual, Inhalational, Topical, and Cutaneous
Key Molecule Types Small Molecule, Recombinant Protein, Synthetic Peptide, Peptide, Fusion Protein, Recombinant Peptide, Cell Therapy, Biologic, Monoclonal Antibody, and Gene Therapy
Leading Companies Eli Lilly and Co, Tonghua Dongbao Pharmaceutical Co Ltd, Novo Nordisk AS, Merck & Co Inc, Jiangsu Hengrui Medicine Co Ltd, AstraZeneca Plc, Sihuan Pharmaceutical Holdings Group Ltd, Adocia SAS, Chong Kun Dang Pharmaceutical Corporation, and Intarcia Therapeutics Inc

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders).
  • Reviews of pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Reviews of key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • Evaluation of Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

3SBio Inc
Abarceo Pharma AB
Adare Pharma Solutions
Addpharma Inc
Adocia SAS
Aerami Therapeutics Inc
Afimmune Biopharma Ltd
Agentix Corp
AgeX Therapeutics Inc
Aju Pharm Co Ltd
Akero Therapeutics Inc
Akston Biosciences Corp
Algiax Pharmaceuticals GmbH
Alms Therapeutics
Alnylam Pharmaceuticals Inc
AlphaMab Co Ltd
Alphamab Oncology
Altimmune Inc
AltrixBio Inc
Amide Technologies Inc
AmideBio, LLC
Amogen Pharma Pvt Ltd
Anagenesis Biotechnologies SAS
Ananda Scientific Inc
Anji Pharmaceuticals Inc
AnyGen Co Ltd
Anyuan Pharmaceutical Technology (Shanghai) Co Ltd
Apcegen Technologies Pvt Ltd
Aphios Corp
Apoglyx AB
APT Therapeutics Inc
Aptamer Sciences Inc
AptamiR Therapeutics Inc
Arecor Therapeutics Plc
Ariddad Therapeutics SL
Arkay Therapeutics LLC
Artery Therapeutics Inc
Asdera LLC
Astellas Pharma Inc
AstraZeneca Plc
Atrogi AB
Autotac Bio Inc
Autotelic Bio Inc
Avolynt Inc
Beijing Eastern Biotech Co Ltd
Beijing Northland Biotech Co Ltd
Beijing QL Biopharmaceutical Co Ltd
Beijing SL Pharmaceutical Co Ltd
Belite Bio Inc
Betagenon AB
Betta Pharmaceuticals Co Ltd
Biocon Ltd
BioEos Ltd
Biogenomics Ltd
BioKier Inc
BioLingus AG
Biomea Fusion Inc
Biora Therapeutics Inc
BioRestorative Therapies Inc
Biotts SA
Biozeus Pharmaceutical SA
Boehringer Ingelheim International GmbH
Bopin (Shanghai) Biomedical Technology Co Ltd
Boryung Pharmaceutical Co Ltd
Braasch Biotech LLC
BrightGene Bio-Medical Technology Co Ltd
C4X Discovery Holdings Plc
Caelus Health
Caldan Therapeutics Ltd
CAR-T (Shanghai) Biotechnology Co Ltd
Carlina Technologies SAS
Carmot Therapeutics Inc
Celdara Medical LLC
Cellebration Life Sciences Inc
Cellix Bio Pvt Ltd
Celon Pharma SA
Centaurus Therapeutics Inc
Center Laboratories Inc
CGeneTech (Suzhou China) Co Ltd
Chain Biotechnology Ltd
Chengdu Di'ao Pharmaceutical Group Co Ltd
Chengdu Easton Biopharmaceuticals Co Ltd
Chengdu Shengdi Medical Company Co Ltd
Chong Kun Dang Pharmaceutical Corporation
Chongqing Chenan BioPharm Co Ltd
Cinnagen Co
Cisen Pharmaceutical Co Ltd
CMG Pharmaceutical Co Ltd
CohBar Inc
Concenter BioPharma Silkim Ltd
ConjuChem LLC
CRISPR Therapeutics AG
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co Ltd
D&D Pharmatech Co Ltd
Daewon Pharmaceutical Co Ltd
Daewoo Pharmaceutical Co Ltd
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Dale Biotech LLC
Delpor Inc
Diabetology (Products) Ltd
Diamyd Medical AB
Diapin Therapeutics LLC
Diasome Pharmaceuticals Inc
DiscoveryBiomed Inc
DNJ Pharma Inc
DNX Biopharmaceuticals Inc
Dong Wha Pharma Co Ltd
Dong-A Socio Holdings Co Ltd
Dong-A ST Co Ltd
DongKoo Bio & Pharma Co Ltd
EastGate Pharmaceuticals Inc
Eccogene (Shanghai) Co Ltd
Efil Bioscience Inc
Egy-Nano Pharma LP
Elevian Inc
Eli Lilly and Co
Emmaus Life Sciences Inc
Empros Pharma AB
EncuraGen Co Ltd
Enesi Pharma Ltd
Enteris BioPharma Inc
Enzene Biosciences Ltd
Enzo Biochem Inc
Epichem Pty Ltd
Eternygen GmbH
Evotec SE
F. Hoffmann-La Roche Ltd
Fochon Pharmaceutical Ltd
Forkhead BioTherapeutics Inc
FortuneRock (China) Ltd
Fujian Haixi New Medicine Creation Co Ltd
Gan & Lee Pharmaceuticals Co Ltd
Generex Biotechnology Corp
Genexine Inc
Genovate Biotechnology Co LTD
Genprex Inc
George Medicines Pty Ltd
Geropharm
GL Pharm Tech Corp
Glaceum Inc
Glucox Biotech AB
Glyscend Inc
Gmax Biopharm LLC
Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangzhou Magpie Pharmaceutical Co Ltd
Gubra ApS
Guizhou Zhongguan Biotechnology Co Ltd
Gusto Global LLC
Hangzhou East China Pharmaceutical Group Co Ltd
Hangzhou Jiuyuan Gene Engineering Co Ltd
Hanmi Pharmaceuticals Co Ltd
HCW Biologics Inc
HEC Pharm Group
HEC Pharma Co Ltd
Hefei Industrial Pharmaceutical Institute Co Ltd
HighTide Therapeutics Inc
HK inno.N Corp
Housey Pharmaceutical Research Laboratories LLC
Hua Medicine Shanghai Ltd
Huadong Medicine Co Ltd
Hualan Biological Engineering Inc
Huons Co Ltd
Hyundai Pharma Co Ltd
i2O Therapeutics Inc
Ildong Pharmaceutical Co Ltd
Imagine Pharma LLC
Immunwork Inc
Immupharma Plc
Immuron Ltd
Impetis Biosciences Ltd
Inflammasome Therapeutics Inc
Innovimmune Biotherapeutics Inc
Intarcia Therapeutics Inc
Integral Molecular Inc
Inventiva SA
Inversago Pharma Inc
Ionis Pharmaceuticals Inc
Japan Tobacco Inc
Jeil Pharmaceutical Co Ltd
Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Lianhuan Pharmaceutical Co Ltd
Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd
Jiangsu T-mab BioPharma Co Ltd
Johnson & Johnson
Kadimastem Ltd
Kallyope Inc
Kaneq Bioscience Ltd
Karyo Biologics LLC
KB Biomed Inc
Klotho Therapeutics Inc
Kolmar Korea Co Ltd
Korea Pharma Co Ltd
Kriya Therapeutics Inc
Kyorin Pharmaceutical Co Ltd
Kyung Dong Co Ltd
Laboratorios Silanes SA de CV
Lannett Co Inc
Lanzhou Institute of Biological Products Co Ltd
Lead Discovery Center GmbH
Lepu Medical Technology (Beijing) Co Ltd
Levim Biotech LLP
Lexicon Pharmaceuticals Inc
LG Chem Ltd
Ligand Pharmaceuticals Inc
LipimetiX Development Inc
Lisata Therapeutics Inc
Livzon Pharmaceutical Group Co Ltd
Lixte Biotechnology Holdings Inc
Longevity Biotech Inc
Lotus Pharmaceutical Co Ltd
Luckwel Pharmaceuticals Inc
Luye Pharma Group Ltd
Lyndra Therapeutics Inc.
Mankind Pharma Ltd
MannKind Corp
MD Healthcare Inc
Medesis Pharma SA
Medlab Clinical Ltd
Melior Pharmaceuticals I Inc
Merck & Co Inc
Mesoblast Ltd
Metabolic Solutions Development Company LLC
Metabolys SAS
Metacrine Inc
Metynex Pharmaceuticals AB
Mito BioPharm LLC
Mitsubishi Tanabe Pharma Corp
Moderna Inc
Moon (Guangzhou) Biological Technology Co Ltd
MRM Health NV
MThera Pharma Co Ltd
MyMD Pharmaceuticals Inc
Naia Ltd
Neuraly Inc
Neurimmune Holding AG
Neurodon LLC
NewG Lab Pharma Co Ltd
NGM Biopharmaceuticals Inc
NIMIUM Therapeutics Inc
Ningbo Kunpeng Biotech Co Ltd
Novartis AG
NovMetaPharma Co Ltd
Novo Nordisk AS
NuSirt Biopharma Inc
NutriBand Inc
NVP Healthcare Co Ltd
Oblique Therapeutics AB
OliPass Corporation
Omeros Corp
Oncosimis Biotech Pvt Ltd
OPKO Health Inc
OptiKira LLC
Oramed Pharmaceuticals Inc
Original BioMedicals Co Ltd
Overseas Pharmaceuticals Ltd
Palatin Technologies Inc
Palisade Bio, Inc
Pano Therapeutics Inc
Panorama Researchama Research
Paras Biopharmaceuticals Finland Oy
Park of Active Molecules
PegBio Co Ltd
Peptron Inc
Pfizer Inc
PharmaCyte Biotech Inc
Pharmasaga Co Ltd
Pila Pharma AB
Polus Inc
Poxel SA
Preveceutical Medical Inc
PrimeGen Global Inc
Prokidney Corp
ProLynx LLC
Prometheon Pharma LLC
ProMIS Neurosciences Inc
Protheragen Inc
Protibea Therapeutics Inc
Prous Institute for Biomedical Research SA
Purzer Pharmaceutical Co Ltd
Qilu Regor Therapeutics Inc
Qoracle Co Ltd
QuiaPEG Pharmaceuticals AB
Ramino-Bio Ltd
Rani Therapeutics LLC
Rebus Holdings Inc
Regenerative Medical Solutions Inc
Remd Biotherapeutics Inc
Remedium Bio Inc
reMYND NV
Renova Therapeutics Inc
Retinset SL
Ridgeline Therapeutics LLC
Rivus Pharmaceuticals Inc
RosVivo Therapeutics Inc
Samik Pharmaceutical Co Ltd
Samjin Pharm Co Ltd
Sanofi
Sanwa Kagaku Kenkyusho Co Ltd
ScandiCure AB
Sciwind Biosciences Co Ltd
Scohia Pharma Inc
Senseion Inc
Sensulin LLC
Seoul Pharma Co Ltd
Serodus ASA
Serpin Pharma LLC
Shaanxi Micot Technology Co Ltd
Shandong Baijidichang Pharmaceutical Co Ltd
Shandong Luye Pharmaceutical Co Ltd
Shanghai Benemae Pharmaceutical Corp
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai HEP Pharmaceutical Co Ltd
Shanghai Innogen Pharmaceutical Technology Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Shionogi & Co Ltd
Shouyao Holding Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Sihuan Pharmaceutical Holdings Group Ltd
Sino Biopharmaceutical Ltd
Sirona Biochem Corp
SJT Molecular Research SL
SK Chemicals Co Ltd
Sosei Group Corp
Sparrow Pharmaceuticals Inc
Stelis Biopharma Ltd
Structure Therapeutics Inc
Sulfateq BV
Sun Pharmaceutical Industries Ltd
Sveikatal Inc
SymbioCellTech LLC
Synokem Pharmaceuticals Ltd
Synthetic Biologics Inc
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Tasly Pharmaceutical Group Co Ltd
Techfields Pharma Co Ltd
The Healthy Aging Co
The United Laboratories International Holdings Ltd
Theertha Biopharma Pvt Ltd
Theracos Inc
Thermalin Inc
Tonghua Dongbao Pharmaceutical Co Ltd
Torrent Pharmaceuticals Ltd
Transdermal Delivery Solutions Corp
Transgene Biotek Ltd
Transira Therapeutics LLC
TTY Biopharm Co Ltd
Twist Bioscience Corp
UGISense AG
Uni-Bio Science Group Ltd
United Biomedical Inc
USV Pvt Ltd
Valin Technologies Ltd
ViaCyte Inc
Viking Therapeutics Inc
vTv Therapeutics Inc
Vybion Inc
Wockhardt Ltd
Wren Therapeutics Ltd
Wuxi Hebang Biotechnology Co Ltd
Xeris Biopharma Holdings Inc
XL-protein GmbH
XOMA Corp
XuanZhu Biological Technology Co Ltd
Yichang Hec Changjiang Pharmaceutical Co Ltd
Yooyoung Pharm Co Ltd
Youngene Therapeutics Co Ltd
Yueyang Pharmaceutical Development (Guangzhou) Co Ltd
Zealand Pharma AS
Zhejiang Doer Biologics Corp
Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang HuaYang Pharmaceutical Co Ltd
Zhuhai United Laboratories Co Ltd
Zih Yuan Tang Biotechnology Co Ltd
Zucara Therapeutics Inc
Zydus Lifesciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Type 2 Diabetes – Overview

Type 2 Diabetes – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Type 2 Diabetes – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Type 2 Diabetes – Companies Involved in Therapeutics Development

Type 2 Diabetes – Drug Profiles

Type 2 Diabetes – Dormant Projects

Type 2 Diabetes – Discontinued Products

Type 2 Diabetes – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Type 2 Diabetes, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Type 2 Diabetes – Dormant Projects, 2022

Type 2 Diabetes – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Type 2 Diabetes, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the key targets of the Type 2 Diabetes pipeline drugs market?

    Some of the key targets of the Type 2 Diabetes pipeline drugs market are Glucagon Like Peptide 1 Receptor, Insulin Receptor, Dipeptidyl Peptidase 4, Sodium/Glucose Cotransporter 2, Adenosine Monophosphate Activated Protein Kinase, Glucagon Receptor, Gastric Inhibitory Polypeptide Receptor, Glucokinase, Glucagon Like Peptide 1, and Free Fatty Acid Receptor 1.

  • What are the key mechanisms of action of the Type 2 Diabetes pipeline drugs market?

    Some of the key mechanisms of action of the Type 2 Diabetes pipeline drugs market are Glucagon Like Peptide 1 Receptor Agonist, Insulin Receptor Agonist, Dipeptidyl Peptidase 4 Inhibitor, Sodium/Glucose Cotransporter 2 Inhibitor, Adenosine Monophosphate Activated Protein Kinase Activator, Gastric Inhibitory Polypeptide Receptor Agonist, Glucagon Receptor Agonist, Glucokinase Activator, Glucagon Like Peptide 1 Activator, and Free Fatty Acid Receptor 1 Agonist.

  • What are the key routes of administration in the Type 2 Diabetes pipeline drugs market?

    Some of the key routes of administration in the Type 2 Diabetes pipeline drugs market are oral, subcutaneous, parenteral, intravenous, transdermal, buccal, sublingual, inhalational, topical, and cutaneous.

  • What are the key molecule types in the Type 2 Diabetes pipeline drugs market?

    Some of the key molecule types in the Type 2 Diabetes pipeline drugs market are small molecule, recombinant protein, synthetic peptide, peptide, fusion protein, recombinant peptide, cell therapy, biologic, monoclonal antibody, and gene therapy.

  • Which are the leading companies in the Type 2 Diabetes pipeline drugs market?

    Some of the leading companies in the Type 2 Diabetes pipeline drugs market are Eli Lilly and Co, Tonghua Dongbao Pharmaceutical Co Ltd, Novo Nordisk AS, Merck & Co Inc, Jiangsu Hengrui Medicine Co Ltd, AstraZeneca Plc, Sihuan Pharmaceutical Holdings Group Ltd, Adocia SAS, Chong Kun Dang Pharmaceutical Corporation, and Intarcia Therapeutics Inc.

Type 2 Diabetes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Type 2 Diabetes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Type 2 Diabetes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Type 2 Diabetes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.